Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought shorting a stock is not forbidden?
Manipulation yes. Shorting is not manipulating
Yes wifisherman, I'm well aware of them - there's little doubt in my mind that IPCI did not go from $3+ to $2 in 2 weeks because investors wanted out... but that it's been forced down by selling from one account to another related account on a never relenting downward push... probably picked up very few loose shares, and instead probably sacrificed more than they gained.
What doesn't make sense to me is how they now expect to accumulate 4 million shares without driving the price to $6.00 to $8.00 in doing so.
The only hope they would have is if they can get the shares directly from IPCI, and I believe that WILL NEVER HAPPEN - I believe the Odidis would lend the company money if necessary for as long as it takes to sign a partnership.
I think the Odidis would have agreed to an issue of maybe 1 million shares for $3.50 - but nothing anywhere near $2.00 nor 4 million shares - and now I believe they would not issue shares to them at any price - the knife cuts both ways.
although all the above is assuming that there actually was an offer for 4 million shares at $2.00 - I'm not sure, but activity sure seems to have followed that logic.
that's the post I remember seeing - thanxs
Are we reading too much in these tea leaves???
You would not sign a deal like this UNTIL patent has been issued, nor would you sign it and make it conditional on patent issuance, you would come to an agreement on terms, cross all the t's, dot all the i's, and be ready to sign on the dotted line as soon as patent is issued.
C'mon patent office - start issuing
This office is made for issuing... and that's just what they'll do... well one of these days this office... is gonna issue one for you. duhh do do duhh do do dughhh
LOL
According to Haddox, the "holy grail" for the pharmaceutical industry is an opioid that delivers relief for patients while preventing abuse by ingestion.
I had noticed that meaningful volume and suppression of share price always started at approx 12:30 pm EST - which suggested that the entity is on the west coast beginning his day at 9:00 a.m. and begin shorting at 9:30 a.m. - yesterday and today the activity started at 11:30 a.m. - which suggests that whoever it is, lives in a region not affected by the daylight saving time - in the US it would be Arizona - but more than likely he/she is in the western part of CANADA - I'm assuming canada does not have daylight saving time??? can anyone affirm that???
According to Haddox, the "holy grail" for the pharmaceutical industry is an opioid that delivers relief for patients while preventing abuse by ingestion.
Looks like you took a photo of the monitor Doog.
Check in your program files for a little program called "snipping tool" - it's bundled as part of windows 7 like notepad.
It lets you capture any segment of the monitor and save it as a jpeg - really easy to use and tremendously useful tool.
He probably has the chart set for "near the money" view instead of "see all"
Suddenly having sold 110,000 shares at an average of $8.00 seems brilliant - although they were necessary sales due to margin calls.
Sure glad I bet on the other horse as it was considerably a safer bet... with as much potential as nwbo.
Now it seems like all the bad news is out on the other horse and it's beginning to come on with nothing but potentially great news ahead of it.
It may allow me to re-accumulate my 190K shares on the cheap - got 15K today.
I believe they actually believed during the last raise that it was a bridge raise and they would be raising at a higher price going forward - but who has not underestimated the time it takes to get something done when dealing with the FDA??? A PR stating they are resuming screening would easily take it to $4.00.
BUT, I am really pissed that they did not do the raise with NW - what is going on here - is LP and NW in a tit for tat here??? I can't believe NW was offered these terms and refused them - they need to show unity or they are cutting off their nose to spite their face!!!
No, not existing institutional investor - existing institutional investorS
I can't imagine that NW would not have accepted these terms - and it would have possibly been seen as a positive - throwing a bone to an investor that, single handedly, kept us afloat for a couple of years - instead they dealt with vultures.
I AM DISGUSTED.
IPCI'S KEPPRA XR HAS BEEN APPROVED
APPROVAL on Levetiracetem
During the "state of the union" speech I thought that maybe the U.S. government might be interested in financing the DC Vax Direct Phase 2 trial(s) or at least facilitate the financing through a 0% or low % loan for about $100 million... would be nice no???
Yes and BTW, Black also has high level connections with the Republican party establishment
on level 2, 100 share bid at 2.31 on ARCA, EDGX, or any other exchange could be covering a 100,000 share bid at 2.30 on ARCA, EDGX, or any other corresponding exchange and you would never know about it... level 3 shows all bids, asks
I think a retail investor is accumulating - they wait till there's a reasonable amount at the ask that they can see on level 2, then enter a buy - just now, probably a 10K buy at 2.35 and it took out all of the 2.33, 2.34 and 2.35 and left it with 4.8K to go on the 2.35
I say retail because he doesn't always get the whole amount filled so he must be going by what he sees on Level 2 - if it was a fund they would be seeing level 3 which shows everything available - also seems he's trying to minimize the # of commissions - he'll probably sit at 2.35 till he's filled there then wait for a gathering on the ask and put in a new bid
All a guess of course - but been going on for 2 days like that, probably someone that was at the conference
Just for insight, how did you come across this stock, and what in particular convinced you to buy into it.
thanxs
The Toronto stock exchange is open today.
IPCI only traded 230 shares (of an average 13K full day trade) so far at 11:30 but it traded at $3.53 canadian which is $2.43 US.
Hopefully a good sign for Tuesday's trading.
some might call me idiot but I am not planning to sell a single share below 20$
So although IPCI doesn't get 180 days of exclusivity on SeroquelXR
god, I love that post
Possibly whoever bought my PUTS already owned the stock to put to me - but if they are naked, someone has to buy 77,700 shares before the end of day tomorrow.
My feeling is that this news is more important than an ANDA approval, and I believe it's caught the attention of major funds - but unlike you and me, they don't do anything without a committee meeting.
So my guess is that we'll be seeing heavier volume and a consistent creeping up share price in the near future as funds take a position.
Present Phase 3 trial is for newly diagnosed GBM.
Do you think the crossover comparator would yield enough information to possibly apply for approval expansion for Recurring GBM???
Just checked to see open interest on next week's PUT options.
Boy, they are mostly mine.
I sold 561 of the 625 $5.00 PUTS, and 212 of the 215 $7.50 PUTS.
So by next friday, someone has to buy 77,300 shares to put to me, assuming IPCI is under $5.00.
Hell, that should drive price up some.
Hoping/Expecting news on monday morning, I decided to roll the dice on 50 $2.50 calls expiring next friday.
Paid 5 cents each + a hefty $39.16 commission - total $289.16
What the hell - last time they announced focalin approval it went from $1.80 to $6.xx in 2 days.
Maybe the volume spike is a leak on news coming.
Would be nice to make $17,500.00 on a $289.16 investment/gamble.
LOL
I have a $50K margin call right now, so I'm hoping for news pre-market monday.
Need +30 cents to close the margin call.
I am counting on a POP in IPCI so I can buy back at $2.30 the XXXX stock I was forced to sell at $10.00, $8.00, and $6.00.
So far throughout this huge downdraft in bios I've only sold 2,300 shares of IPCI - so if IPCI pops first, I may yet be made whole down the road.
I have been thinking along the same line - paying taxes on a depressed NWBO share price with the hope/expectations that any meaningful growth beyond $3.50 would be tax free
However I found out that any appreciation has to remain in the Roth IRA for 5 years or it will be taxed as though it was earned income (same as regular IRA) - you can take out the original $3.50 tax free but all growth has to remain in the Roth IRA for 5 years to be tax free.
I've stopped buying green bananas, so now I'm sitting on the fence regarding this matter.
Egalet Enters into Development Collaboration and License Agreement with Shionogi Limited for Abuse-deterrent Oral Hydrocodone Opioid Product Candidates
Egalet licenses rights to preclinical hydrocodone-based product candidates to be developed using Egalet’s proprietary abuse-deterrent delivery technology; Egalet to receive upfront and milestone payments plus potential royalties on net sales
Nov 26, 2013
Malvern, PA - November 26, 2013 - Egalet Corporation (“Egalet”) announced today that it has entered into a definitive collaboration and license agreement with Shionogi Limited (“Shionogi”) for the development and potential commercialization of multiple oral abuse-deterrent hydrocodone opioid product candidates using Egalet’s proprietary technology.
Egalet will receive a $10 million upfront payment from Shionogi and Shionogi has agreed to purchase up to approximately $15 million in common stock in a private placement to close concurrently with Egalet’s recently filed initial public offering. Egalet is eligible to receive milestone payments upon development and approval of products under the agreement, which may exceed $300 million if multiple products are approved. Shionogi will fund all costs associated with the development of these products. Shionogi will also have exclusive global rights to commercialize the resulting products. If any products developed under the collaboration are approved for marketing, Egalet is eligible to receive tiered royalties, ranging from the mid-single digits to the low double digits based on the net sales of such products, as well as sales-based milestone payments that could exceed $100 million based on the attainment of specified sales thresholds.
http://egalet.investorroom.com/news-releases?item=19
$10 million up front for a PRECLINICAL drug - at the stage Rexista is at, it should be worth $40 Million upfront - and milestones totaling $500 million + 20 to 30% royalties.
ps - Shionogy has on Dec 3rd 2015 given all rights back to egalet - could it be they find grater value in IPCI's platform???
It appears that Yahoo does not retain the comparison stock - click comparison above the chart and type in NWBO... and click the various time frames - NWBO outperforms in all.
http://finance.yahoo.com/echarts?s=ARGS+Interactive#{%22allowChartStacking%22:true}
It seems like Linda is hell bent on keeping the whole pie, but I think that in her best interest, and all present shareholders she should carve out a portion of it and learn to share.
This is what I would like to see BEFORE any further dilution, particularly if there needs to be warrants granted.
GBM is a worldwide malice and the need for an effective treatment is probably as great ex US and Europe - so why not carve out a piece of the pie for a major Asian oncology pharma.
My suggestion -
~A $500 Million deal for DC VaxL broken down as follows:
~$100 Million up front - like right NOW (that would minimize if not eliminate dilution)
~$100 Million on FDA approval of DC VaxL for GBM
~$100 Million each on FDA approval for any 3 additional cancer indications utilizing DC VaxL for operable tumors
~10% to 15% of GROSS revenues up to aggregate $1 Billion - 20% of GROSS thereafter
~Partner would be given full access to NWBO generated data, but would self-pay for any future developments
~Right of first refusal for any future partnership of DC Vax Direct
That would send the shorts scurrying - Short squeeze the hell out of them.
ps - royalty recentages would be debatable - not much else would be.
We're all very aware that "in your mind" management is solely responsible for NWBO's poor price performance... but what exactly do you attribute ARGS "pitiful" price performance to.
http://finance.yahoo.com/echarts?s=ARGS+Interactive#{%22allowChartStacking%22:true}
Fell free to click on all the time frames from 1 day to 2 years - in each and every case NWBO has outperformed - wait let me rephrase that - ARGS has UNDERPERFORMED NWBO.
WHY??? - is it that ARGS management is even MORE incompetent than NWBO???
Truthfan - Buiding on my previous post and expanding on your post -
I just noticed that I have a sell order for 30,173 NWBO shares at $50.00 - which is the amount I was told I was voting on - however I actually have 53,173 shares... so it appears that 30,173 they could not lend out - but the 23K that I don't have a sell order on were lent out and deny me voting rights.
So I'm guessing that placing even a ridiculous sell order in keeps them from lending the shares... I always douted that that did anything... nor do I now know that they actually adhere to those rules, but it does appear so.
Kind of ticks me off that someone who borrowed and shorted my shares and is working against me might be voting my shares.
Very strange - I just got a phone call from a service saying their records show that I haven't voted my NWBO shares yet and if I would like to vote them over the phone as per the boards recommendations.
After having done so I asked how many shares I was voting and the IRA acct was correct, but the regular acct was 20K less than I actually own.
Inquiring as to the why one acct was showing 20K less shares didn't get me anywhere - so just gave up on trying to get an answer that made sense.
Anyone here with a possible reason??? I'm wondering if 20K are borrowed for shorting???
I think all this gives Ondra a "black eye" that may never fade away.
Who is going to be willing to hire a company that does not disclose that one of their staff has a conflict of interest with one of their clients???
The most prudent thing for Ondra to do is to cut all ties with "the wolf" as she was fully aware of the conflict from day one and obviously did not disclose it.
That's only if their burn rate remained the same, which it's not likely.
A great deal is going to change going forward.
In order to get FDA approval on a drug you need to demonstrate that you can produce it at commercial quantity. that would incur a sizeable investment on IPCI's part - they do have a $100 million shelf and can issue stock to raise money - after a POP in the share price if they do - but I would prefer they take on a partner for Rexista and get a sizeable up front payment - my guess is $40 million - rather than dilute.
Exactly my feelings.
I've said many times that in all my years of investing in emerging biotechs, I have never seen a better risk/reward scenario.
I now want to add that in all my years of investing in emerging biotechs, I have never seen a more frugal and fiscally responsible corporation.
I believe they still have a few millions $ on their ATM, however they have always been very frugal with it's use - and all raises have to date been at above $3.20... I believe they will continue that tradition and only sell shares if there's a pop above that, if not I believe that, as in the past, the Odidi's will probably fund it for a million $ or so at a reasonable % rate.
So Handa`s ANDA most likely have the 180 days of exclusivity .
And they also settled whit AZ to be able to come to market in the US as of November 2016 .
they do not say 180 day exclusivity on the 400mg!!!!!
Who have the 400 mg exclusivity ?
Major Shareholder Wants Inquiry Into Northwest Biotherapeutics Allegations -- Update
Today 5:19 PM ET (Dow Jones)Print
By Denise Roland
LONDON--A major shareholder is urging biotechnology firm Northwest Biotherapeutics Inc. to hold an inquiry into allegations about the governance of the company by Chairman and Chief Executive Linda Powers.
Neil Woodford, a U.K. fund manager well-known for investing in the biotech industry, has sent a letter to the board of the Bethesda, Md.-based company to recommend it establish an independent special committee to investigate the claims. The letter was contained in a filing with the U.S. Securities and Exchange Commission.
He proposed the board appoint Elliott Leary, a former special agent of the Federal Bureau of Investigation who now conducts investigations for the global risk-management firm Freeh Group International Solutions LLC, as a nonexecutive director.
If appointed, Mr. Leary then would convene a special committee of nonexecutive directors to investigate the allegations, which were made largely by an equities research group, and which raise questions about what the research group says are the company's financial dealings with vehicles related to Ms. Powers.
The Woodford letter, which was dated on Tuesday, concluded: "In this way, we and other investors can then be satisfied that the Company will have the benefit of a fully independent investigation."
Ms. Powers in interviews on Friday and Saturday with The Wall Street Journal denied there have been any financial irregularities between Northwest and entities related to her. She termed the allegations as "baloney." She said payments for services to such entities had been cleared by the Northwest board, independently audited and filed where necessary with regulators.
She said Northwest had repeatedly been subjected to efforts by analysts and others "to throw mud against the wall at us." She said she "shared the view" of Mr. Woodford that there should be an investigation and "wanted to see this stuff put to rest once and for all."
Mr. Woodford's letter said Northwest Biotherapeutics' board had earlier this month agreed in principle to his proposal and that Mr. Leary had met with the board last week. Company officials confirmed the meeting took place.
Ms. Powers said the company planned to appoint a new board member and launch an independent review "on a rapid basis and soon" and that while the search for a nonexecutive director is focusing on Mr. Leary, the process hasn't been completed.
Phase Five Research, which carries out analysis of health-care and biotech companies, last month published a scathing report raising questions about Northwest's technology in development and accusing Ms. Powers, of using the company "as her personal checking account to financially support her investment" in other private ventures. In its report, Phase Five noted that it and its employees may take long or short positions in companies they cover.
Phase Five claimed that since 2004 around $310 million in cash, shares, warrants, options and other benefits had been transferred from Northwest to the Toucan Group, an entity controlled by Ms. Powers and her husband.
Ms. Power said Northwest didn't know how Phase Five came up with the $310 million figure. Les Goldman, who heads Northwest's business development, said any payments to a company related to Ms. Power would have been made to a Toucan portfolio firm Cognate BioServices in return for further development and manufacture of Northwest's cancer treatment for use in clinical trials involving hundreds of patients.
The two executives pointed out that a large percentage of payments to Cognate would have been in unregistered and non-tradable locked-up shares.
The activist move is an unusual one for Mr. Woodford, who typically adopts a passive stance. He made his first investment--$25 million--in the company last year. He has since invested an additional $70 million into the company across two subsequent fundraisings, and currently holds a 28% stake.
Of that total, he agreed to his most-recent investment, of $30 million, just days before Phase Five Research made its allegations. Mr. Woodford said in the letter that he "only became aware of these allegations after the completion of our recent investment" in the company.
Mr. Woodford is one of only a small number of life-science specialists investors in the U.K., and his backing is highly sought by biotechs.
Northwest Biotherapeutics is developing a treatment that involves altering a patient's own immune cells to make them more effective at fighting tumors. Its most advanced treatment is for brain cancer, but it is also conducting early-stage research in ovarian cancer. The company says it is investigating the potential of the approach in a wide range of solid cancer tumors.
Write to Denise Roland at Denise.Roland@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 28, 2015 17:19 ET (22:19 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
you need to take into consideration that there was a 1/16 stock reverse split since most of these options were granted.
For instance, the $10.56 pre reverse split price was 66 cents and the $8.80 pre split was actually 55 cents... as to the quantity granted, multiply the amount they have now by 16 to arrive at the quantity they were granted at the time.
there was a previous 1/15 reverse split in June of 2007, so I believe Bosch's 52 shares were pre 2007 - since they expired Jan 2015 they were probably issues Jan 2005 and had a 10 year expiration date... the quantity is as such - 52 shares x 16 x 15 = 12,480 - more than likely 12,500 shares @ $5.00 strike.
My warrants were issued @ 40 cents pre split or 6.40 post split - expiring October 2017.
In case anyone... as I did... mistakenly thinks the disclaimer is part of any article written by Malik or Cenkos, IT IS NOT.
the disclaimer
"The firm admits in its disclaimer that when it publishes any report on its site, it should be assumed that the company, employees and clients have taken an investment position in the stock, be that a long or short bet, "and therefore stands to realize significant gains in the event that the price of the stock increases or declines".
Got lucky this AM and picked up 5K more at $4.91.
100K to go.
How does it go?... 5K a day keeps the blues away???